Skip to main content
Premium Trial:

Request an Annual Quote

Mobidiag Inks Distribution Agreements in Europe, Middle East for Dx Products

NEW YORK – Mobidiag said on Tuesday that it has signed exclusive distribution agreements for its Amplidiag and Novodiag molecular diagnostic products in Europe and the Middle East.

Specifically, the Espoo, Finland-based firm signed distribution agreements for its products with Alab in Poland and the Ukraine; Biogenetix in Romania; and Theranostica in Israel.

Mobidiag's Amplidiag and Novodiag instruments and assays are designed for syndromic infectious disease testing. Novodiag is an automated, cartridge-based system that uses real-time PCR and microarray technology to detect infectious diseases and antibiotic resistance in approximately one hour. Amplidiag is an automated system that does batch nucleic acid extraction and PCR plate setup from stool samples.

"We are extremely pleased to have further expanded our commercial footprint into additional international territories," Mobidiag CEO Tuomas Tenkanen said in a statement. "Our highly versatile and complementary Amplidiag and Novodiag diagnostic solutions continue to gain traction internationally. We are in ongoing discussions with several distribution partners in a range of international markets as customers look for fast, accurate, and affordable diagnostic solutions to a wide range of infectious diseases."

Earlier this year Mobidiag also signed exclusive European and Middle Eastern distribution agreements with Helix2 in Greece; UAB in Latvia and Lithuania; and Ibn Rushd Medical & Scientific Equipment in Kuwait.

In July, Mobidiag signed an exclusive distribution agreement with Pro Med Diagnostics in several African countries.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.